Bioventus Inc. (BVS) News
Filter BVS News Items
BVS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BVS News Highlights
- For BVS, its 30 day story count is now at 2.
- Over the past 13 days, the trend for BVS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC and HA are the most mentioned tickers in articles about BVS.
Latest BVS News From Around the Web
Below are the latest news stories about BIOVENTUS INC that investors may wish to consider to help them evaluate BVS as an investment opportunity.
Bioventus Names Robert Claypoole as President and Chief Executive OfficerSeasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Driving Revenue and Operating Margin GrowthDURHAM, N.C., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that its Board of Directors has appointed Robert (Rob) Claypoole as Bioventus’ President and Chief Executive Officer and a member of its Board of Directors, effective January 10, 2 |
Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee OsteoarthritisDURHAM, N.C., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Aetna™ Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna™ Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. DUROLANE will be one |
Smith & Nephew inks $180M CartiHeal buyout, capitalizing on Bioventus turmoil to land knee implantBioventus’ protracted buyout bid ultimately fell apart and opened the door to Smith & Nephew. |
Bioventus Inc. (NASDAQ:BVS) Q3 2023 Earnings Call TranscriptBioventus Inc. (NASDAQ:BVS) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Thank you for standing by. My name is Dustin, and I will be your conference operator today. This time, I would like to welcome everyone to Bioventus Inc. Third Quarter 2023 Earnings Conference Call. [Operator Instructions] At this time, I’d like to turn […] |
Bioventus Inc (BVS) Reports Q3 2023 Financial Results, Raises Full Year 2023 Financial GuidanceDespite a decrease in net sales, the company's financial results exceeded expectations with improved performance in Pain Treatments and continued cost management |
Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial GuidanceDURHAM, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 30, 2023. Q3 Financial Summary: Net Sales of $120.8 million, down $7.9 million, or 6.1%, year-over-year as reported (6.3% constant currency*). Excluding revenues from divested wound assets, underlying organic sales decreased $0.6 million, or 0.5% year-over-year |
Bioventus to Report Third Quarter of Fiscal Year 2023 Financial Results on November 7, 2023DURHAM, N.C., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2023 before the market opens on Tuesday, November 7, 2023. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial |
Bioventus (BVS) to Report Q3 Earnings: What's in the Cards?On Bioventus' (BVS) third-quarter 2023 earnings call, investors' focus is likely to be on the sales numbers of its three business units - pain treatments, restorative therapies and surgical solutions. |
3 Value Medical Stocks to Buy for Safety Amid Market VolatilityWe have narrowed our search to three value stocks from the Medical sector. These are PHG, RDNT and BVS. |
Bioventus to Present at the Cantor Global Healthcare ConferenceDURHAM, N.C., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 1:50 p.m. ET. A live audio webcast of the fireside chat will be available on the “Investors” section of the Company’s website at www.bioventus.com and will be availabl |